Table 2.
Survival rates
| Author | Sample size, no. | Median OS, months | Confidence interval, 95% | 1-year OS, % | 2-year OS, % | 3-year OS, % | 5-year OS, % | Median PFS, months |
|---|---|---|---|---|---|---|---|---|
| Jolissaint 28 | 81 a | 24.9 | 20.3–29.6 | 85.2 | 46.9 | 21.0 | 4.9 | NR |
| 56 b | 18.1 | 14.1–26.6 | 62.5 | 33.9 | 12.5 | 1.8 | NR | |
| Pietge 29 | 12 | 23.9 | NR | 75.0 | 41.7 | 33.3 | 0.0 * | 10.1 |
| Cercek 26 | 38 c | 25.0 | 20.6–not reached | 89.5 | 50.6 * | 43.7 * | NR | 11.8 |
| 10 d | NR | NR | 70.0 | 40.0 | NR | NR | 12.8 | |
| Wright 27 | 16 | 39 | 32.7–51.3 | 86.9 * | 67.3 * | 50.5 * | 6.3 | 9.0 |
| Konstantinidis 25 | 78 | 30.8 | NR | 86.7 * | 59.3 | 36.4 * | 22.0 * | 12.0 |
| Konstantinidis 24 | 44 | 29.3 | 26.6–31.9 | NR | NR | 22.7 | 11.4 | NR |
| Kemeny 31 | 18 e | 31.1 | 14.0–33.6 | 86.5 * | 62.0 * | NR | NR | 8.5 |
| Jarnagin 30 | 26 f | 29.5 | 21.3–32.7 g | 88.2 | 67.6 | 29.4 | NR | 7.4 |
| Endo 23 | 28 | 22 | 20–not reached | NR | NR | NR | NR | NR |
OS Overall survival, PFS progression free survival, NR not reported
*Results derived from Kaplan–Meier curves
aN0 patients
bN1 patients
cMSKCC cohort
dWashington University in St. Louis cohort
eEighteen iCCA patients, 4 HCC patients
fTwenty-six iCCA patients, 8 HCC patients
gConfidence interval derived from Kemeny et al.